FAIRFAX, Va.--(BUSINESS WIRE)--Health technology company Vibrent Health, developers of the Learning Health System (LHS), the technology platform of the National Institutes of Health Precision Medicine Initiative/All of Us Research Program, expands its digital health solutions business into Europe through a partnership with Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS). Vibrent Health will work with the Europe-led consortium on developing digital health programs featuring predictive analytics designed to monitor and help improve treatment for depression, multiple sclerosis, and epilepsy.

RADAR-CNS is conducting research using a range of medical-grade sensors, such as electro-cardiograms, as well as a growing portfolio of consumer-grade sensors, including accelerometers and smartphone applications, that collect participant data from surveys and smartphone sensors. The program will also use an end-to-end, data-streaming solution for aggregating, collecting and serving data for real-time and post-hoc analysis along with dashboards to support data quality and data export in large-scale trials.

“The Vibrent Health team has been a core part of the software design and Agile development process, providing great experience and resourceful solutions in the development of the RADAR-base platform,” said Amos Folarin, MD, of Kings College London. "Vibrent Health provides a unique value to RADAR-base with its expertise in architecting large-scale health research systems. We look forward to continuing our partnership to build a truly extensible ecosystem for health data collection.”
Vibrent Health is collaborating on RADAR-CNS and RADAR-base, the open source tools that are being developed to support this initiative, along with a consortium of health organizations, including King’s College London, Janssen Pharmaceutica (Johnson & Johnson), and BioGen.

“We are excited to be at the forefront of digital health research with RADAR-CNS as we endeavor to learn and understand more about health using smartphones and wearables to potentially transform how chronic disorders are treated,” said Mark Begale, director of strategic partnerships for Vibrent Health. “The technology we are honing for these types of programs offers great promise in helping researchers, health care practitioners and participants better understand and improve the delivery of care and improve the quality of life for patients.”

The program is funded by the Innovative Medicines Initiative, a public-private partnership established between the European Federation of Pharmaceutical Industries and Associations and the European Union.

Health IT Homepage